Report overview
Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.
Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
This report aims to provide a comprehensive presentation of the global market for Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics. This report contains market size and forecasts of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics in global, including the following market information:
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market was valued at US$ 7854.6 million in 2022 and is projected to reach US$ 11030 million by 2030, at a CAGR of 5.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The market would gain traction in the developing regions of Asia-Pacific and third-world countries such as Africa and Latin America. The large undiagnosed patient population, rapid urbanization, rising disposable income, improved government funding towards cancer and growing awareness about prostate cancer would be some of the prime reasons responsible for the unparalleled market growth in these regions. However, oncologists/urologists reluctance towards adoption of these premium treatments in countries like India and China would continue to remain a key challenge for the leading innovators.
We surveyed the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Segment Percentages, by Type, 2022 (%)
Oral Therapy
Injectable Therapy
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Segment Percentages, by Application, 2022 (%)
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astellas Inc.
Johnson & Johnson
Sanofi S.A
Dendreon Corporation
Bayer AG
Outline of Major Chapters:
Chapter 1: Introduces the definition of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics, market overview.
Chapter 2: Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
